Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Goodwill & Intangibles (2020 - 2026)

10x Genomics' Goodwill & Intangibles history spans 6 years, with the latest figure at $66.8 million for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles rose 231.19% to $66.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.8 million, a 231.19% increase, with the full-year FY2025 number at $66.8 million, up 231.19% from a year prior.
  • Goodwill & Intangibles hit $66.8 million in Q4 2025 for 10x Genomics, down from $69.3 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for TXG hit a ceiling of $69.3 million in Q3 2025 and a floor of $4.5 million in Q1 2021.
  • Historically, Goodwill & Intangibles has averaged $25.0 million across 5 years, with a median of $23.8 million in 2023.
  • Biggest five-year swings in Goodwill & Intangibles: surged 548.97% in 2022 and later crashed 82.79% in 2023.
  • Tracing TXG's Goodwill & Intangibles over 5 years: stood at $29.9 million in 2021, then dropped by 8.49% to $27.4 million in 2022, then crashed by 82.79% to $4.7 million in 2023, then skyrocketed by 328.4% to $20.2 million in 2024, then skyrocketed by 231.19% to $66.8 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for TXG at $66.8 million in Q4 2025, $69.3 million in Q3 2025, and $19.2 million in Q2 2025.